The FDA authorized Pfizer’s COVID-19 booster for children 12 to 15 and reduced the wait time between the vaccine’s primary series and booster to five months.
The FDA authorized Pfizer’s COVID-19 booster for children 12 to 15 and reduced the wait time between the vaccine’s primary series and booster to five months.
The FDA authorized Pfizer’s COVID-19 booster for children 12 to 15 and reduced the wait time between the vaccine’s primary series and booster to five months.
The FDA authorized Pfizer’s COVID-19 booster for children 12 to 15 and reduced the wait time between the vaccine’s primary series and booster to five months.
The FDA authorized Pfizer’s COVID-19 booster for children 12 to 15 and reduced the wait time between the vaccine’s primary series and booster to five months.